CN118416082A - 布林西多福韦的制剂 - Google Patents

布林西多福韦的制剂 Download PDF

Info

Publication number
CN118416082A
CN118416082A CN202410393564.XA CN202410393564A CN118416082A CN 118416082 A CN118416082 A CN 118416082A CN 202410393564 A CN202410393564 A CN 202410393564A CN 118416082 A CN118416082 A CN 118416082A
Authority
CN
China
Prior art keywords
brincidofovir
concentration
dose
infusion
bcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410393564.XA
Other languages
English (en)
Chinese (zh)
Inventor
穆罕默德·安娜若·卡比尔
奥丁·约翰·纳德尔
厄玛·玛丽莎·格罗西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergency Biological Defense Action Lansing LLC
Original Assignee
Emergency Biological Defense Action Lansing LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergency Biological Defense Action Lansing LLC filed Critical Emergency Biological Defense Action Lansing LLC
Publication of CN118416082A publication Critical patent/CN118416082A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202410393564.XA 2016-06-28 2017-06-28 布林西多福韦的制剂 Pending CN118416082A (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201662355844P 2016-06-28 2016-06-28
US62/355,844 2016-06-28
US201662394665P 2016-09-14 2016-09-14
US62/394,665 2016-09-14
US201762446213P 2017-01-13 2017-01-13
US62/446,213 2017-01-13
US201762465053P 2017-02-28 2017-02-28
US62/465,053 2017-02-28
US201762507397P 2017-05-17 2017-05-17
US62/507,397 2017-05-17
US201762512825P 2017-05-31 2017-05-31
US62/512,825 2017-05-31
CN201780040478.9A CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
PCT/US2017/039804 WO2018005676A1 (en) 2016-06-28 2017-06-28 Formulations of brincidofovir

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780040478.9A Division CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂

Publications (1)

Publication Number Publication Date
CN118416082A true CN118416082A (zh) 2024-08-02

Family

ID=59313330

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202210134248.1A Pending CN114569547A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN202411127002.7A Pending CN119139329A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN201780040478.9A Pending CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN202410393564.XA Pending CN118416082A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN202210134248.1A Pending CN114569547A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN202411127002.7A Pending CN119139329A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN201780040478.9A Pending CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂

Country Status (12)

Country Link
US (3) US20170368082A1 (enExample)
EP (2) EP3474822B1 (enExample)
JP (3) JP6878473B2 (enExample)
CN (4) CN114569547A (enExample)
AU (2) AU2017290703B2 (enExample)
CA (1) CA3024886A1 (enExample)
DK (1) DK3474822T3 (enExample)
ES (1) ES3037596T3 (enExample)
FI (1) FI3474822T3 (enExample)
PL (1) PL3474822T3 (enExample)
PT (1) PT3474822T (enExample)
WO (1) WO2018005676A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899215A (zh) 2013-11-15 2016-08-24 奇默里克斯公司 十六烷氧基丙基膦酸酯的形态
ES3037596T3 (en) * 2016-06-28 2025-10-03 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
CN114073772A (zh) * 2020-08-18 2022-02-22 上海市公共卫生临床中心 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途
CN114558022B (zh) * 2022-02-16 2023-11-17 华中农业大学 布林西多福韦在制备抗伪狂犬病毒药物中的应用
CN114732821A (zh) * 2022-04-24 2022-07-12 华中农业大学 西多福韦的前药在制备防治非洲猪瘟药物中的应用
JP7417339B1 (ja) * 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
WO2025072782A1 (en) * 2023-09-29 2025-04-03 Symbio Pharmaceuticals Limited Brincidofovir for treatment of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233770B1 (en) 1999-12-03 2008-02-13 The Regents of The University of California at San Diego Phosphonate compounds
JP4136340B2 (ja) * 2000-08-18 2008-08-20 武田薬品工業株式会社 注射剤
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US20070003608A1 (en) 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
CN102702260A (zh) * 2007-04-27 2012-10-03 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
JP2011116658A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
BR112012002551A2 (pt) 2009-08-03 2017-06-13 Chimerix Inc composição e métodos de tratamento de infecções virais e tumores induzidos por vírus
JP2013509433A (ja) 2009-10-30 2013-03-14 キメリクス，インコーポレイテッド ウイルス関連疾患を処置する方法
DK2508170T3 (en) 2009-12-03 2015-09-21 Jiangsu Hengrui Medicine Co LIPOSOM OF IRINOTECAN OR ITS HYDROCHLORIDE AND ITS PROCEDURE
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
EP2611818B1 (en) 2010-08-31 2016-08-24 Chimerix, Inc. Phosphonate ester derivatives and methods of synthesis thereof
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
US20150087619A1 (en) 2012-04-27 2015-03-26 Chimerix, Inc. Method of mitigating virus associated end-organ damage
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN105899215A (zh) * 2013-11-15 2016-08-24 奇默里克斯公司 十六烷氧基丙基膦酸酯的形态
ES3037596T3 (en) * 2016-06-28 2025-10-03 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir

Also Published As

Publication number Publication date
JP6878473B2 (ja) 2021-05-26
US20230210873A1 (en) 2023-07-06
PT3474822T (pt) 2025-08-21
JP2019519570A (ja) 2019-07-11
US12485131B2 (en) 2025-12-02
DK3474822T3 (da) 2025-08-18
CN114569547A (zh) 2022-06-03
WO2018005676A1 (en) 2018-01-04
EP4295853A3 (en) 2024-03-06
AU2017290703A1 (en) 2018-12-13
EP3474822B1 (en) 2025-07-09
CA3024886A1 (en) 2018-01-04
EP4295853A2 (en) 2023-12-27
US20170368082A1 (en) 2017-12-28
AU2023204117A1 (en) 2023-07-13
PL3474822T3 (pl) 2025-11-03
ES3037596T3 (en) 2025-10-03
AU2017290703B2 (en) 2023-03-30
JP2021143178A (ja) 2021-09-24
CN119139329A (zh) 2024-12-17
JP2023033538A (ja) 2023-03-10
EP3474822A1 (en) 2019-05-01
CN109475497A (zh) 2019-03-15
FI3474822T3 (fi) 2025-08-15
JP7221485B2 (ja) 2023-02-14
AU2023204117B2 (en) 2025-03-20
US20200138835A1 (en) 2020-05-07
JP7407984B2 (ja) 2024-01-04

Similar Documents

Publication Publication Date Title
JP7221485B2 (ja) ブリンシドフォビルの製剤
JP7359827B2 (ja) 治療薬のｃｎｓ送達
JP6045491B2 (ja) 治療薬のｃｎｓ送達
TR201810815T4 (tr) Tnf-alfa antikorlarının farmasötik formülasyonları.
EP3505154A2 (en) Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof
CN103877012A (zh) 一种细辛脑注射剂及其制备工艺
HK40075964A (en) Formulations of brincidofovir
HK40105712A (en) Formulations of brincidofovir
PETERSEN et al. Digoxin–trimethoprim interaction
TWI857310B (zh) 酮咯酸胺丁三醇的液體組合物、其製備方法及應用
WO2024224373A1 (en) Levothyroxine dispersions
Azri‐Meehan et al. Repeated‐Dose Toxicity Studies in Nonclinical Drug Development
CA3220425A1 (en) Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection
CN118697690A (zh) 一种巴氯芬鼻脑递释组合物
KR20150030761A (ko) 화합물 1-(6-｛[6-(4-플루오로페닐)[1,2,4]트리아졸로[4,3-b]피리다진-3-일]술파닐｝-1,3-벤조티아졸-2-일)-3-(2-모르폴린-4-일에틸)우레아를 포함하는 항종양 조성물
Timman et al. D. Dekker, MJ Dorresteijn, M. Lodeweges-Welzen, D. Burger, P. Pickkers
Dekker et al. Parenteral human use of bilirubin; a re-introduction for translational research.
HK1218719B (zh) 治疗试剂的cns递送
MXPA94003569A (en) Stable quinolone and naphthyridine premix formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40115807

Country of ref document: HK

CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Lansing Martin, Michigan, United States Luther 3500 Jindao North

Applicant after: Emergency Biological Defense Action Lansing LLC

Address before: Delaware, USA

Applicant before: Emergency Biological Defense Action Lansing LLC

Country or region before: U.S.A.

CB02 Change of applicant information